(Q36115009)

12 August 2017

The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone (English)

1 reference

12 August 2017

1 reference

1 reference

1 reference

Wardley AM

1

1 reference

12 August 2017

Jayson GC

2

1 reference

12 August 2017

Goldsmith DJ

3

1 reference

12 August 2017

Venning MC

4

1 reference

12 August 2017

Ackrill P

5

1 reference

12 August 2017

Scarffe JH

6

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 September 1998

1 reference

British Journal of Cancer

12 August 2017

1 reference

12 August 2017

78

1 reference

12 August 2017

6

1 reference

12 August 2017

774-776

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1998.577

12 August 2017

0 references

cites work

Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062981

VAD chemotherapy as remission induction for multiple myeloma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062981

Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062981

Amyloidosis (AL). Clinical and laboratory features in 229 cases

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062981

Primary systemic amyloidosis--a diagnostic primer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062981

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062981

Treatment of AL amyloidosis without myeloma

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062981

Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062981

Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062981

Primary amyloidosis associated with multiple myeloma. Predictors of successful therapy

23 September 2018

1 reference

12 December 2020

Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component

1 reference

12 December 2020

Response rates and survival in primary systemic amyloidosis

1 reference

12 December 2020

Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1998.577

1 reference

12 August 2017

1 reference

12 August 2017

1 reference